Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kristen Kipping-Johnson"'
Autor:
Lindsay Alpert, John Hart, Sunil Narula, Bryan Peterson, Leah Chase, Namrata Setia, Murtuza Rampurwala, Kelly Moore, Ugne Markevicius, Theodore Karrison, Samantha Lomnicki, Uzma D. Siddiqui, Chih-Yi Liao, Kiran K. Turaga, Daniel V.T. Catenacci, Kristen Kipping-Johnson, Blase N. Polite, Hedy L. Kindler, Yuan Ji, Mitchell C. Posner
Publikováno v:
Journal of Clinical Oncology. 38:356-356
356 Background: 1-yr OS is ~40% for HER2- & ~55% for HER2+ advanced (aGEA). Targeted therapies (tx) have had limited benefit due to molecular heterogeneity. Methods: This phase 2a study of a personalized tx strategy (PTS) enrolled newly diagnosed aGE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::048fb34dc2bf2b18dd0fa35eb9e767c3
https://doi.org/10.1200/jco.2020.38.4_suppl.356
https://doi.org/10.1200/jco.2020.38.4_suppl.356
Autor:
Andrea Amico, Kenisha Allen, Steven Brad Maron, Sunil Narula, Ardaman Shergill, Christine Racette, Daniel V.T. Catenacci, Brooke Elizabeth Phillips, Murtuza Rampurwala, Samantha Lomnicki, Jennifer Ibe, Manish R. Sharma, Erin Wojak, Grace K. Suh, Smita S. Joshi, Shayan Rayani, Blase N. Polite, Hedy L. Kindler, Kristen Kipping-Johnson, Mark Kozloff
Publikováno v:
Journal of Clinical Oncology. 36:TPS198-TPS198
TPS198 Background: Targeted therapies (tx) in GEA have had limited efficacy despite recognition of numerous ‘targetable’ molecular events. This may be due to the molecular heterogeneity (MH) that exists between patients (pts), within the primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa0fc9a48d13474478a354bda42d2a87
https://doi.org/10.1200/jco.2018.36.4_suppl.tps198
https://doi.org/10.1200/jco.2018.36.4_suppl.tps198
Autor:
Lucy A. Godley, Gordana Raca, Nancy Glavin, Paul Geeleher, Richard A. Larson, Bonnie LaCroix, Fan Wang, Michael J. Thirman, Kristen Kipping-Johnson, Aritro Nath, Rong Stephanie Huang, Elizabeth Rich, Divya Lenkala
Publikováno v:
Journal of Investigative Medicine. 64:935-936
The interpretation and implementation of large-scale genetic profiles into clinical practice remains a challenge despite substantial growth in our understanding of genetic contributors to drug response. Most current omic studies focus on identifying
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7ff09e6a32e64a1c81ac9316f1091b8
https://doi.org/10.1136/jim-2016-000120.50
https://doi.org/10.1136/jim-2016-000120.50
Autor:
Nancy Glavin, Divya Lenkala, R. Stephanie Huang, Fan Wang, Michael J. Thirman, Kristen Kipping-Johnson, Aritro Nath, Richard A. Larson, Bonnie LaCroix, Lucy A. Godley, Gordana Raca, Paul Geeleher
Publikováno v:
Cancer Research. 76:2039-2039
The interpretation and implementation of large-scale genetic profiles into clinical practice remains a challenge despite substantial growth in our understanding of genetic contributors to drug response. Most current omic studies focus on identifying
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5b5789800f6d52dad15f1e134d8832c
https://doi.org/10.1158/1538-7445.am2016-2039
https://doi.org/10.1158/1538-7445.am2016-2039